Use of protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
First Claim
Patent Images
1. A pharmaceutical composition comprising a SF1, SF2, SF3, SF4, SF5, or SF6 protein and/or a functional fragment thereof, a nucleic acid molecule encoding a SF1, SF2, SF3, SF4, SF5, or SF6 protein and/or a functional fragment thereof and/or an effector/modulator of said nucleic acid molecule and/or said protein or protein fragment.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention discloses proteins expressed by the developing pancreas, and polynucleotides, which identify and encode these proteins. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.
-
Citations
40 Claims
- 1. A pharmaceutical composition comprising a SF1, SF2, SF3, SF4, SF5, or SF6 protein and/or a functional fragment thereof, a nucleic acid molecule encoding a SF1, SF2, SF3, SF4, SF5, or SF6 protein and/or a functional fragment thereof and/or an effector/modulator of said nucleic acid molecule and/or said protein or protein fragment.
-
22. Use of a SF1, SF2, SF3, SF4, SF5, or SF6 nucleic add molecule or a polypeptide encoded thereby or a fragment or a variant of said nucleic add molecule or said polypeptide and/or an effector/modulator of said nucleic acid or polypeptide for the manufacture of a medicament for the treatment of pancreatic diseases (e.g. diabetes such as insulin dependent diabetes mellitus and/or non insulin dependent diabetes mellitus and/or LADA), obesity, metabolic syndrome and/or other metabolic diseases or dysfunctions for controlling the function of a gene and/or a gene product which is influenced and/or modified by a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide.
-
23. Use of the SF1, SF2, SF3, SF4, SF5, or SF6 nucleic acid molecule or use of a polypeptide encoded thereby, or use of a fragment or a variant of said nucleic acid molecule or said polypeptide, or use of an effector/modulator of said nucleic acid molecule or said polypeptide for identifying substances capable of interacting with a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide in vitro and/or in vivo.
- 24. A non-human transgenic animal exhibiting a modified expression of a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide.
-
28. A method of identifying a (poly)peptide involved in the regulation of energy homeostasis and/or metabolism in a mammal comprising the steps of
(a) contacting a collection of (poly)peptides with a SF1, SF2, SF3, SF4, SF5, or SF6 homologous polypeptide or a fragment thereof under conditions that allow binding of said (poly)peptides; -
(b) removing (poly)peptides which do not bind and (c) identifying (poly)peptides that bind to said SF1, SF2, SF3, SF4, SF5, or SF6 homologous polypeptide. - View Dependent Claims (31, 32, 33, 38)
-
-
29. A method of screening for an agent which effects/modulates the interaction of a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide with a binding target comprising the steps of
(a) incubating a mixture comprising (aa) a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide or a fragment thereof; -
(ab) a binding target/agent of said SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide or fragment thereof; and
(ac) a candidate agent under conditions whereby said polypeptide or fragment thereof specifically binds to said binding target at a reference affinity;
(b) detecting the binding affinity of said SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide or fragment thereof to said binding target to determine an affinity for the agent, and (c) determining a difference between affinity for the agent and reference affinity.
-
-
30. A method for screening for an agent, which effects/modulates the activity of a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide, comprising the steps of
(a) incubating a mixture comprising (aa) a SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide or a fragment thereof, and (ab) a candidate agent under conditions whereby said SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide or fragment thereof exhibits a reference activity, (b) detecting the activity of said SF1, SF2, SF3, SF4, SF5, or SF6 polypeptide or fragment thereof to determine an activity for the agent; - and
(c) determining a difference between activity for the agent and reference activity.
- and
-
39. Use of a SF1, SF2, SF3, SF4, SF5, or SF6 nucleic acid molecule or of a fragment thereof for the production of a non-human transgenic animal which over- or under-expresses the SF1, SF2, SF3, SF4, SF5, or SF6 gene product.
-
40. Kit comprising at least one of
(a) a SF1, SF2, SF3, SF4, SF5, or SF6 nucleic acid molecule or a functional fragment or an isoform thereof; -
(b) a SF1, SF2, SF3, SF4, SF5, or SF6 amino acid molecule or a functional fragment or an isoform thereof;
(c) a vector comprising the nucleic acid of (a);
(d) a host cell comprising the nucleic acid of (a) or the vector of (c);
(e) a polypeptide encoded by the nucleic acid of (a), expressed by the vector of (c) or the host cell of (d);
(f) a fusion polypeptide encoded by the nucleic acid of (a);
(g) an antibody, an aptamer or another effector/modulator against the nucleic acid of (a) or the polypeptide of (b), (e), or (f) and/or (h) an anti-sense oligonucleotide of the nucleic acid of (a).
-
Specification